Melio Bio - the first company in the MTM London Pod
Molecule to Medicine (MTM) and its drug discovery partner, Sygnature Discovery are proud to announce the launch of the fourth company in the MTM ecosystem, and the first in the newly formed London Pod focused on cardiometabolic diseases.
Melio Bio is focused on the discovery and development of inhibitors of GPCRs implicated in cardiometabolic disease including Type 2 diabetes, pulmonary hypertension, obesity, and stroke.
MTM co-creates, builds, and scales biotech companies. Run by entrepreneurs for entrepreneurs, the MTM ecosystem integrates experienced drug discovery expertise with stage appropriate, agile, operational infrastructure that results in companies that are efficient, cost effective, focused and great places to work. By partnering with Sygnature Discovery, a world-leading integrated drug discovery partner with broad expertise and track record in GPCRs, and metabolic disease, Melio Bio will deliver best-in-class inhibitors to potentially treat patients suffering with metabolic diseases that are poorly treated by existing therapeutic options.
